title: [Phase II clinical trial of nedaplatin in advanced non-small cell lung cancer].
abstract: OBJECTIVE
  The aim of this study was to observe the efficacy and the side effects of nedaplatin in treatment of non-small cell lung cancer (NSCLC).
  
  
  METHODS
  This is a multi-center phase II clinical trial. The previously chemotherapy treated patients with NSCLC were administrated nedaplatin alone. Nedaplatin was given at 100 mg/m2, i.v., repeated every 3 weeks. The chemonaive patients with NSCLC were randomized to two groups. The combination trial group was given with nedaplatin + vindesine regimen, and the combination control group with cisplatin + vindesine.
  
  
  RESULTS
  Of 138 patients, 16 were in the nedaplatin single drug group; 60 were in the combination trial group; and 62 were in the combination control group. All of the 16 cases in the single drug group, which were treated with platinum previously, achieved 12.5% of response rate. And the combination trial group and control group had a very similar response rate, which were 26.7% versus 25.8%, respectively. The incidence rates of neutropenia and anemia were similar in the two groups. But the incidence rate of thrombocytopenia was higher in the trial group than that in the control group. Nedaplatin has a possibility to result in mild nausea/vomiting.
  
  
  CONCLUSIONS
  Nedaplatin is an effective platinum drug in the treatment of NSCLC, not only for no previously chemotherapy patients, but also for those patients resistant to cisplatin/carboplatin. Nedaplatin has a good clinical tolerance. And the main adverse reaction was myelosuppression, especially thrombocytopenia.
authors.affiliation: Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China. ruihuaxu@163.net
authors.forename: Rui-hua
authors.initials: RH
authors.lastname: Xu
authors.forename: Zhong-zhen
authors.initials: ZZ
authors.lastname: Guan
authors.forename: Wen-qi
authors.initials: WQ
authors.lastname: Jiang
authors.forename: He
authors.initials: H
authors.lastname: Huang
authors.forename: Xiao-hua
authors.initials: XH
authors.lastname: Hu
authors.forename: Wei-min
authors.initials: WM
authors.lastname: Xie
authors.forename: Xing-gen
authors.initials: XG
authors.lastname: Li
authors.forename: Ya-li
authors.initials: YL
authors.lastname: Liu
authors.forename: Liang-xi
authors.initials: LX
authors.lastname: Pan
authors.forename: Ai-di
authors.initials: AD
authors.lastname: Dai
authors.forename: Wu
authors.initials: W
authors.lastname: Zhuang
authors.forename: Chun
authors.initials: C
authors.lastname: Zhang
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Ma
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin